We're expecting the results of the Johns Hopkins Medical School study of the effects of anatabine citrate, the active ingredient in Anatabloc, any minute. To say that I'm excited is an understatement, but it is not the only piece of the puzzle coming together.
I've told you in the past about various tests performed at the Roskamp Institute of the active ingredient in Star Scientific's (NASDAQ: STSI) Anatabloc on humanized animals. Last week, however, a major scientific journal, the European Journal of Pharmacology, published a peer-reviewed article about some of those results titled “Anti-inflammatory Activity of Anatabine via Inhibition of STAT3 Phosphorylation.”
While more details from the Roskamp studies have now been revealed, the important point is that they have attained real scientific credibility. Allow me quote from the company's press release:
“Star Scientific Inc. today announces that new anatabine research has been accepted by and published online in the European Journal of Pharmacology. In a series of studies, researchers at the Roskamp Institute demonstrated that anatabine can suppress brain inflammation in animal models of Alzheimer's disease, inflammation in the blood in mice and inflammation induced in human blood once removed from the body. This peer-reviewed data supporting the view that anatabine has widespread anti-inflammatory properties were published in a paper, titled ‘Anti-inflammatory Activity of Anatabine via Inhibition of STAT3 Phosphorylation.’ The anatabine used in these studies is made under Star Scientific's patented process and is the main ingredient in its Anatabloc dietary supplement.
“In one study, the highly inflammatory molecule LPS, which is released from bacteria during human infections, was injected into mice. Subsequently, there were expected large increases in inflammatory molecules in the blood, spleen and kidney; however, when cotreated with anatabine, there were statistically significant large decreases in these inflammatory molecules in the blood, spleen and kidney. The spleen, in particular, showed marked suppression of inflammatory molecule release during cotreatment with anatabine.
“In addition, the Roskamp Institute team showed that in a mouse model of Alzheimer's disease, supplementation with anatabine resulted in a significant suppression of inflammatory markers, especially a marker called TNF-alpha, which is known to be raised in Alzheimer's disease. This finding complements a previous study by the Roskamp Institute showing reduction of the amyloid protein in this mouse model of Alzheimer's after treatment with anatabine. The reduction of the accumulation of amyloid and inflammation in the brain are known to be intimately linked, one increasing the other. Therefore, anatabine's reduction of both amyloid levels and inflammation encourage the hypothesis that anatabine may be a useful treatment for Alzheimer's disease.”
No offense, but I would much rather hear about an epiphany on the part of somebody we haven't heard from yet... even if it is Jim Cramer (I don't like him, but for some reason lots of folks listen to him).